药捷安康宣布达成重磅授权合作!东阳光药新药IND……

医药经济报
Nov 03

药捷安康宣布达成一项超8亿美元授权合作11月3日,药捷安康(南京)科技股份有限公司发布公告宣布,公司与Neurocrine Biosciences, Inc.订立一项付特许权使用费的专利转让及研究合作协议,以开发NLRP3抑制剂,用于治疗多种疾病。截图来源:药捷安康公告根据该协议,Neurocrine获授予在大中华区以外开发、制造及商业化药捷安康NLRP3药物平台中的NLRP3抑制剂的独家权利,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10